HC Wainwright & Co. initiated coverage on Histogen with a new price target
$HSTO
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. initiated coverage of Histogen with a rating of Buy and set a new price target of $2.40
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2021 | $2.40 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of Histogen with a rating of Buy and set a new price target of $2.40
Canaccord Genuity reiterated coverage of Histogen with a rating of Buy and set a new price target of $4.00 from $5.00 previously
Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00
Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO), today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The Special Meeting, which will be reconvened for a final time on January 4, 2024, will continue to be held v
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO) today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The reconvened Special Meeting on December 14, 2023 will continue to be held via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM. In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on Octob
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of Septem
SC 13G/A - Histogen Inc. (0001383701) (Subject)
SC 13G/A - Histogen Inc. (0001383701) (Subject)
SC 13G/A - Histogen Inc. (0001383701) (Subject)
15-12G - Histogen Inc. (0001383701) (Filer)
DEFA14A - Histogen Inc. (0001383701) (Filer)
425 - Histogen Inc. (0001383701) (Subject)
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. "Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections (ABSSSI), including those related to methicillin res
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus ("MRSA") and evaluating our caspase-1 inh
Closed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We continue to focus on execution of IND enabling activities for HST 004 in spinal disc regeneration, exploration of testing emricasan in ani
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
4 - Histogen Inc. (0001383701) (Issuer)
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. "We are very excited about Dr. Spada joining our management team. Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors," said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief E
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t
A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr